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ABSTRACT
IMPACT OF OXYBENZONE ON INNATE IMMUNE SIGNALING
MAY 2022
BRENDA SOUZA MEDEIROS, B.S., UNIVERSITY OF MASSACHUSETTS
AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
DIRECTED BY: LAURA N. VANDENBERG & SALLIE S. SCHNEIDER
EDCs are commonly thought to bind or interfere with estrogen, androgen, progesterone,
thyroid, and retinoid receptors. Oxybenzone is considered to be an endocrine disrupting
chemicals and approximately 97% of people in the United States were found to have BP3
in their urine. This thesis will address how BP3 effects the innate immune system, in
particular myeloid cells. My Master’s thesis aims to address two main overarching
questions. Does BP3 alter macrophage polarization, cytokine/chemokine secretion,
viability in vitro? Does exposure to BP3 in vivo during pregnancy/lactation affect the
RNA expression of cytokines and immunosuppressant factors associated with myeloid
population? It is unknown how BP3 impacts immune subpopulations in a neoplastic
setting. Additionally, it is important to consider how these effects may contribute to
malignant behaviors. My thesis evaluates the effects of BP3 on the Raw 264.7 cell lines
as well as tumor tissues from mice exposed to BP3 during pregnancy and lactation. We
hypothesized that BP3 exposures induce changes in myeloid cell interactions in the
immune system through ER mediated mechanisms. We anticipated that BP3 would
increase growth and migration of 4T1 cells through indirect signals imparted by myeloid
cell populations. We also hypothesized that there will be a decrease in T cell proliferation
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following BP3 exposure and an alteration in gene expression consistent with a shift from
Th1 to Th2. Finally, we expected that BP3 exposure would increase the number of
myeloid cells in mouse tumors. Our research shows that oxybenzone appears to enhance
the pro-inflammatory state of RAW264.7 cells and may result in release of unidentified
factors that can impact 4T1 cell anchorage independent cell growth in these proinflammatory conditions. BP3 may also impact the metabolic activity of recovering
RAW264.7 cells following LPS induced activity. Additionally, BP3 may impact the
release of factors from macrophages that control T cell activation induced proliferation.
By using the p53-/- mouse tumors we found that exposure to 3mg/kg/day BP3 during
pregnancy and lactation did alter IDO1 RNA expression but this was not associated with
markers of immunosuppressive cell types.

iv

TABLE OF CONTENTS
Page
ABSTRACT ..................................................................................................................... iii
LIST OF FIGURES ......................................................................................................... vii
CHAPTER
I. ENDOCRINE DISRUPTING CHEMICALS AND THE IMMUNE SYSTEM.............1
Endocrine Disrupting Chemicals.............................................................................1
Oxybenzone (BP3)………………………………………………………...2
Adverse effects associated with BP3……………………………...5
Immune System………………………………………………………………...…7
Immune Responses to BP3………………………………………………..9
Hypothesis Statement………………………………………………………….…12
Study Objectives…………………………………………………………………12
II. BP3 EFFECT ON A TUMOR CELL LINE AND A MONOCYTE CELL LINE.......15
Macrophages……………………………………………………………………..15
Plasticity of macrophages..........................................................................16
Macrophages and tumors...............................................................17
Chemokines………………………………………..……..18
Macrophages and breast development……...……20
Endocrine disrupting chemicals (EDCs) and
macrophage interactions…………………22
BPA and macrophages…………...24
Results……………………………………………………………………………25

v

Triple Negative Model……………………………………………...……25
Monocyte Model Raw 264.7……………………………………..30
M1………………………………………………………..32
TAMs…………………………………………….33
Conclusion…………..………………….………………………………………..39
III. IMMUNE EFFECT OF BP3 ON A p53-/- TUMOR MODEL……………...............47
Introduction ...........................................................................................................47
Results…………………………………………………………….……………...47
Conclusion…………………………………………………………………….…54
IV. DISCUSSION AND CONCLUSION.........................................................................58
Discussion .............................................................................................................58
Conclusion……………………………………………………………………….62
APPENDIX : METHODS………………………………………………………...……..64
BIBLIOGRAPHY..............................................................................................................69

vi

LIST OF FIGURES
Figure

Page

1. The effect of 30uM BP3 on 4T1 cell gene and protein expression…………………...40
2. The effect of 30uM BP3 on M0 cells (Raw 264.7) gene and protein expression……..41
3. The effect of 30uM BP3 on TAMs (Raw 264.7 & 4T1 co-culture) gene and protein
expression…………………………………………………………………………..…....42
4. The effect of 30uM BP3 on Raw 264.7 cells stimulated with LPS towards M1
phenotype……………………………………………………………………………..….43
5. The effect of 30uM BP3 on recovery of RAW264.7 macrophages following a proinflammatory signal……………………………………………………………………...44
6. The effect of 30uM BP3 on gene expression of Raw264.7 cells treated with 4T1
conditioned media………………………………………………………………………..45
7. The effect of 30uM BP3 on T cells directly treated with 30uM BP3 and indirectly
through M0 conditioned media…………………………………………………………..46
8. The p53-/- mouse model exposed to oxybenzone during pregnancy and lactation…...55
9. Gene expression of immune markers in a p53-/- mouse model……………………….56
10. Protein expression of immune and angiogenic markers in p53-/- mouse model
exposed to 3000 µg/kg/day BP3 during pregnancy and lactation……………………….57

vii

CHAPTER 1
ENDOCRINE DISRUPTING CHEMICALS AND THE IMMUNE SYSTEM
Endocrine Disrupting Chemicals
Endocrine disrupting chemicals (EDCs) are substances that interfere with
hormone biosynthesis, metabolism, or action, leading to a disruption in homeostasis or
reproduction. They are thought of as any natural or synthetic compound that interferes
with the hormonal or homeostatic system’s ability to communicate with its environment
(Diamanti-Kandarakis et al. 2009). Endocrine disruptive chemicals spread through food
consumption, water, air, contaminated soil, and the use of consumer products. These
chemicals are found in pesticides, fungicides, industrial chemicals, plasticizers,
nonylphenols, metals, pharmaceutical agents and phytoestrogens (Yilmaz et al. 2020).
The U.S. Environmental Protection Agency (EPA) defines EDCs as “an exogenous agent
that interferes with synthesis, secretion, transport, metabolism, binding action, or
elimination of natural blood-borne hormones that are present in the body and are
responsible for homeostasis, reproduction, and developmental process.” By interacting
with hormone receptors they can alter hormone synthesis and even the transport of
metabolic processes that are essential during development (Arya et al. 2020).
EDCs are commonly thought to bind or interfere with estrogen, androgen,
progesterone, thyroid, and retinoid receptors. EDCs can be categorized as androgenic and
antiandrogenic as well as a thyroid hormone receptor agonist or antagonist. They have
been shown to affect both the female and male reproductive system in animal models
(Diamanti-Kandarakis et al. 2009). However, they can act not only through nuclear
hormone receptors, but also nonnuclear steroid and nonsteroidal hormone receptors
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including, membrane ERs, neurotransmitter receptors, and even the aryl hydrocarbon
receptor (AhR) (Diamanti-Kandarakis et al. 2009). Perhaps of greater concern is the
observation that some EDCs can modify DNA methylation or histone acetylation
resulting in transgenerational affects (Anway & Skinner, 2006). A cross-sectional study
examined the connection of individual and combined EDCs with infertility. They found
that women have 5-10 times higher EDC levels than men (Calafat et al. 2008).
The endocrine system is highly conserved among mammals allowing for
translatable research done in animal models, however there has also been increasing
numbers of epidemiological studies that aim to discover the EDC burden of disease in
humans (Gore, 2015). Specific effects to the female reproductive system include
impairing processes in ovarian development, disrupting steroid hormone levels, reduced
fertility, and even abnormal puberty. In relation to the male reproductive system, studies
have shown that hormone disruption can influence semen qualities, lead to testicular
abnormalities, and is associated with human testicular cancer (Gore, 2015).
Oxybenzone (BP3)
The first sunscreen was developed in the 1930s to prevent UV-B and in the 1970s
sunscreen further developed to protect against UV-A (Rebut, 1990). In the 1980s
oxybenzone (Benzophenone-3/BP3) was approved by the FDA to be used in sunscreens.
BP3 is used as a short wave UVB and UVA light absorber at concentrations up to 6% in
sunscreens.
In terms of broad-spectrum performance (UVA) BP3 just meets the FDA cutoff with a
critical wavelength absorbance of 370 nm. This suggests that BP3 may not be the most
effective chemical for protection against UVA (Dinardo 2018). It is also used in plastics
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as a UVB absorber and stabilizer (Dinardo 2018) and is approved by the FDA as an
indirect food additive (Calafat et al. 2008) to prevent polymer or food photodegradation
(Calafat et al. 2008). Plastic products that can contain oxybenzone include, food
packaging, medical devices, vinyl floors, cosmetics, and even cleaning supplies (Arya et
al. 2020). The prevalence of sources and pollution have resulted in detectable levels of
BP3 in surface water, drinking water, and wastewater (Calafat et al. 2008). Today BP3 is
an emerging human and environmental contaminant (Dinardo, 2018).
EDCs can have longer or shorter half-lives depending on the compound and the
model system. The half-life of BP3 is 15-18 hours in rats (Arya et al. 2020). BP3 is
conjugated with glucuronic acid in the liver, which makes it water-soluble and able for
excretion through urine (Gonzalez et al. 2006). In the body, BP3 undergoes 2 phases of
biotransformation. In rats, after oral and dermal administrations of 100 mg BP-3/kg body
weight (Kadry et al. 1995; Okereke et al. 1993, 1994, 1995), the parent compound and
three oxidative metabolites (2,4-dihydroxylbenzophenone, 2,2´-dihydroxy-4methoxybenzophenone, and 2,3,4-trihydroxybenzophenone) were detected in plasma,
tissues, and urine. Urine was the major route of excretion; BP-3 and its metabolites were
excreted mainly as glucuronide conjugates (Kadry et al. 1995; Okereke et al. 1993).
In humans, the rate of systematic absorption of BP3 has been estimated as 1-2%
via topical application (Hayden, 1997). Repeated application of sunscreens with BP3
increases the concentration of BP3 in urine and shows greater systemic absorption
(Gonzalez et al. 2006). In some cases, as much as 10% of the applied dose can be
absorbed systemically. (Jiang,1999).
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Approximately 97% of people in the United States were found to have BP3 in
their urine based on a study that examined 2,517 urine samples from the United States
general population (older than 6 years) in 2003-2004 (Calafat 2008). Additionally, BP3
can react with chlorine and produce hazardous by-products (Dinardo, 2018). These
oxidative metabolites identified in the rat study were also found in human urine. (Felix,
1998).
A study of urine BP3 in the NHANES population found the limit of detection
(LOD), calculated as 3S0, where S0 is the standard deviation as the concentration
approaches zero (Taylor 1987), was 0.34 µg/L. We detected BP-3 in 96.8% of the 2,517
samples at concentrations ranging from 0.4 to 21,700 µg/L. In particular, females were
3.5 times more likely than males, and nonHispanic whites were 6.8 times more likely
than non-Hispanic blacks to have BP-3 concentrations above the 95th percentile (Calafat
et al. 2008). In a cohort of 304 women undergoing infertility treatment, BP3 exposure
was positively associated with women who did moderate/heavy outdoor work which
confirms sunscreen as a source for BP3 exposure (Minguez-Alarcon et al. 2019).
Research has raised concern of whether BP3 should continue to be used in
personal care products although many unknowns remain to be explored to understand its
effects in the human body. In particular, a recent study assessing the systemic absorption
of 6 sunscreen active ingredients, including BP3, found that these chemicals surpassed
the FDA threshold plasma concentration (0.5ng/mL) after systemic absorption and
remained in the plasma for at least 3 days after last use (Matta 2020). These results
suggest that exposures that occur after dermal exposures are longer lasting than
previously estimated, and that BP3 metabolism is less efficient, allowing it to remain in
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circulation for days or even weeks in some individuals. Furthermore, among 48
participants, 14 also reported rashes after application. The effects of BP3 once it is
systemically absorbed are not fully understood, therefore there remains a need for
research to determine its effects and the mechanisms involved in any hazardous outcomes
that are observed.
Adverse effects associated with BP3
Research has shown that BP3 may be acting as a xenoestrogen; this means that it
can bind to the estrogen receptor (ER) and mimic estrogen to produce harmful effects.
BP3 was found to skew phenotypic sex of 12 day old zebrafish, from less male to more
female. In addition to this BP3 also interfered with the maturation stages of zebrafish
gonads. Although concentrations of BP3 used were above those found in the aquatic
environment, this reveals an estrogenic or antiandrogenic effect of BP3 on zebrafish
(Kinnberg et al. 2015).
A study conducted with MCF-7 breast cells found that BP3 is a bioactive
chemical that is weakly estrogenic and can also exhibit anti-estrogenic and antiandrogenic effects in vitro (Schlumpf, 2001: Schreurs, 2004). Of particular interest is that
BP3 has been demonstrated to induce DNA damage in several cell types including breast
epithelial cells (Majhi, 2020 Kim, 2018). This effect was dependent on the ER,
implicating the receptor in its mechanism of action, but did not depend on strong
transcriptional activity of the receptor. Additionally, BP3 has been negatively associated
with morphological changes in the mammary gland in numerous studies using rodents. In
the first study, exposure to BP3 during pregnancy and lactation was found to alter
mammary gland morphology and function in mice. Exposure to 3000ug BP3/kg/day
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during this critical period produced morphological changes that were observed long after
exposures ended, suggesting these effects were permanent. This study suggests that
exposures to xenoestrogens during pregnancy and lactation can have long-lasting effects
on morphology of the mammary gland, consistent with other recent studies that have
found that this period of life is vulnerable to environmental agents (LaPlante, 2018).
Additional studies have revealed that the offspring from BP3-exposed dams
exhibited similar results. In females exposed to low doses during perinatal development,
BP3 reduced mammary cell proliferation and decreased the number of cells expressing
ERα (Matouskova, 2020). Combined, these studies suggest that BP3 may have adverse
effects on ductal development during critical windows of susceptibility and may also
produce permanent effects on sons and daughters exposed during perinatal development
(Matouskova, 2020).
Epidemiological studies have also revealed associations between BP3 exposures
and harmful health outcomes in human populations. A case-control study was conducted
using a Nanjing Medical University Birth Cohort (China) with 101 patients with
Hirschspung’s disease - a neonatal intestinal abnormality derived from the failure of
enteric neural crest cells migration to hindgut during embryogenesis - and 322 controls.
Women submitted questionnaires and spot urine samples that were used to quantify BP3
exposures. The urine samples taken after pregnancy were assumed to represent consistent
levels of BP3 in that individual that would be similar to their BP3 exposures during
weeks 5–12 of pregnancy (the time period where intestinal development occurs),
although this was not actually demonstrated to be true. Additionally, 101 patients and 103
controls, who were chosen from university affiliated hospitals and had received surgical
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and non-surgical treatments, provided colon tissue samples for analysis. BP3 exposure
was found to be associated with Hirschsprung’s disease (Huo 2016).
Another study examined urinary BP3 metabolites from 404 multiethnic women in
NYC who participated in the Children’s Environmental Cohort study from Mount Sinai
hospital. Samples were taken in their third trimester, along with infant size at birth.
Statistical analyses revealed that high concentrations of BP3 were associated with a
decrease in birth weight among girls (Wolff, 2008). This supports the notion that
chemicals with endocrine disrupting effects can alter the prenatal development of
progeny (Ngalame et al., 2013; Veiga-Lopez et al., 2013). Collectively, these studies
support the characterization of BP3 as a xenoestrogen, as well as an endocrine disruptor
(La Merrill, 2020) with activities of concern that warrant further study.
The Immune System
The function of the immune system is to prevent or limit infection. It can detect
and differentiate between self and foreign, as well as healthy and unhealthy cells. Each
cell type in the immune system has a different function to produce the correct immune
response (NIH, 2021). The immune system can be divided into two categories, innate and
adaptive immunity. Innate immunity occurs immediately as genetically encoded receptors
detect pathogen-associated patterns. Specific cell types that belong to the innate category
include neutrophils, eosinophils, basophils, mast cells, monocytes, dendritic cells, and
macrophages. Innate cells can initiate adaptive immune responses, which include
activation of B and T cells. These cells recognize specific antigens to eliminate foreign
or unhealthy tissues. B cells make antibodies and T cells have several functions including
killing infected cells and initiating additional immune responses.
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This thesis project will focus on the innate cell types, in particular myeloid cells. I
have chosen to focus on these cell populations because their activity can be controlled by
estrogen; they are also responsible for orchestrating the trafficking of other cell
populations, as well as providing signals to control the type of activity and they have
been demonstrated to interact with tumor cells to affect survival migration and cancer
stem cell activity. Specific cell types of interest to this thesis project are monocytes,
macrophages and dendritic cells.
Monocytes are immature cells that can differentiate into macrophages or
dendritic cells depending on the cytokines present. Both cell types are important for
antigen presentation to the adaptive immune cells, however the dendritic cell is the most
potent initiator and modulator of the immune response (Banchereau, 1998). Dendritic
cells sample large areas of the tissue through their extensive dendritic network to capture
and process antigens and display large amounts of major histocompatibility-peptide
complexes (MHC) at their surface. They also upregulate stimulatory molecules and
migrate to lymphoid organs, the spleen, and lymph nodes where they interact with
antigen-specific T cells (Banchereau, 1998). An increased presence of these immune cells
indicate stimulation of the immune system. On the other hand, dendritic cells can also be
tolerizing, which is important to control inflammation, but may help tumors evade the
immune system.
Macrophages have a strong phagocytic activity necessary to remove dead and
dying cells as well as detect bacteria. They are important for releasing signals involved
in wound healing and can also polarize towards a tolerizing or immune suppressive
phenotype. Since these cells are derived from the same precursor cell they often express
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similar proteins, but particular membrane molecules such as F4/80 and differences in the
levels of other proteins can distinguish them.
Once T cells are activated by dendritic cells, they can interact with other cells
including B cells to initiate antibody formation, macrophages which enable cytokine
release, and other targets specific for lysis (Banchereau, 1998). Dendritic cells process
molecules into antigens that can be recognized by B cells. B cells are the precursors of
antibody-secreting cells and directly recognize native antigens through B-cell receptors
(Banchereau, 1998). Additionally, they can activate T cells by using a specific MHC. T
lymphocytes require the antigen to be processed by an antigen presenting cell (APC)
(Banchereau, 1998). T-cell antigen receptors recognize fragments of antigens bound to
molecules of the MHC on the surface of APCs (Banchereau, 1998).
T cells can be divided into two categories, CD8+ T cells and CD4+ T cells. The
major subsets of interest of CD4+ T cells are T helper cells, TH1 and TH2 cells (NIH,
2021). Extracellular antigens that have entered the endocytic pathway of the APC are
processed and presented to T-helper cells by the MHC class II molecules. T-helper cells
have the potential to have a profound immune-regulatory effect (Banchereau, 1998).
Specifically, TH1 cells coordinate immune responses against intracellular microbes and
produce molecules to activate additional immune responses such as macrophages. TH2
cells coordinate immune responses to combat extracellular pathogens. Regulatory T cells,
also known as Tregs, monitor and inhibit the activity of other T cells (NIH, 2021).
Immune Responses to BP3
Many cell types within immune populations express ERs and this may explain
how exposure to BP3 could alter immune activity. In vivo and in vitro mouse model
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experiments showed that pregnancy levels of estrogen typically induce FoxP3+ T
regulatory cells in splenocytes as well as ovarian tissue (Tai, 2008). Increases in estrogen
are also associated with changes in T cell polarity. Th2 cytokines (TGFβ and IL4) are
upregulated whereas Th1 cytokines (IFNγ and IL2) are decreased by estrogen (Salem,
2004). Finally, estrogen is associated with changes in chemokine related gene expression.
For example, 17β-estradiol has been demonstrated to increase chemokine receptors
(CCR1-5 in T lymphocytes) and CXCL12 and CXCR4 in breast cancer cell lines (Mo,
2005). If BP3 is acting as an estrogen receptor agonist (or antagonist), we may expect to
see alterations in these pathways.
BP3 has the potential to cause harm to the immune system as an allergen, but the
mechanism of action for the effects of BP3 on cells in the immune system is not fully
understood. In a study assessing allergens due to sunscreen application, it was found that
among 23,908 patients, 70% observed an inflammatory effect when they were
administered a topical cream with a 10% concentration of BPS. The inflammatory
response remained relatively high (64% of patients) after application of a 3%
concentration of BP3 (Warshaw, 2013). Another study explored the inflammatory effect
of four UV filters, including BP3, and observed a 1.1-1.5-fold increase in various
inflammatory cytokines associated with macrophages such as TNFα and IL6. In an in
vitro study using THP-1 cells that had been differentiated into macrophage-like cells,
BP3 influenced cytokine gene expression. This study further supports research showing
the allergy risk of BP3 by suggesting that the release of inflammatory cytokines may
aggravate allergic or asthmatic symptoms (Ao, 2018).
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BP3 increases the expression of genes associated with M2 macrophage
polarization in a subset of patient-derived breast tissue explants (Gregory, 2020). BP3 has
the potential to stimulate cytokines and chemokines associated with myeloid populations
that are polarized towards M2. M2 macrophages are known to secrete proteins important
for wound healing and these proteins can promote the migration of tumor cells. BP3’s
increasing effect on M2 polarization suggests that this endocrine disrupting chemical may
cause a pro-metastatic signal (Gregory, 2020).
Finally, there is also evidence that BP3 can adversely affect other tissues and
organs of the body, including tissues that are strongly impacted by immune cell function.
For example, the adverse effects of BP3 on the gut were shown in a study using
Carassius auratus, a species of goldfish. The fish were exposed to varying concentrations
of BP3, and it was observed that BP3 accumulation in the liver and intestine is time and
dose dependent (Zhang, 2020). BP3 can induce effects in the immune, endocrine, and
metabolic systems and increase the risk of fish being infected by pathogenic
microorganisms. This study also showed that short term BP3 exposure causes a
significant increase in biomarkers specific to endocrine disrupting compounds (Zhang,
2020).
My Master’s thesis aims to address two main overarching questions. Does BP3
alter macrophage polarization, cytokine/chemokine secretion, viability in vitro? Does
exposure to BP3 in vivo during pregnancy/lactation affect the RNA expression of
cytokines and immunosuppressant factors associated with myeloid population? It is
unknown how BP3 impacts immune subpopulations in a neoplastic setting. Additionally,
it is important to consider how these effects may contribute to malignant behaviors.
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Hypothesis statement
We hypothesized that BP3 exposures induce changes in myeloid cell interactions
in the immune system through ER mediated mechanisms. We anticipated that BP3 would
increase growth and migration of 4T1 cells through indirect signals imparted by myeloid
cell populations. We also hypothesized that there will be a decrease in T cell proliferation
following BP3 exposure and an alteration in gene expression consistent with a shift from
Th1 to Th2. Finally, we expected that BP3 exposure would increase the number of
myeloid cells in mouse tumors. My thesis evaluates the effects of BP3 on the Raw 264.7
cell lines as well as tumor tissues from mice exposed to BP3 during pregnancy and
lactation.
Chapter Study Objectives
Chapter 2: AIM 1; In this chapter I will discuss the BP3 effect on a triple negative
breast cancer cell line (4T1) and a monocyte cell line (RAW 264.7). The following
questions will be addressed:
2.1 Question: Does BP3 affect the growth, migration, or gene expression in a model of
triple negative breast cancer (ERalpha negative)?
2.2 Question: Does a direct exposure to BP3 alter anchorage independent growth or stem
like gene expression in 4T1 cells? Does BP3 enhance the secretion of factors from
macrophages that facilitate anchorage independent growth of 4T1 cells?
2.3 Question: Does BP3 alter the cytokine or chemokine expression of the RAW 264.7
macrophage cell line? Does BP3 affect polarization in the absence of other signals? Does
it alter LPS induced pro-inflammatory activity? Does BP3 affect tumor associated gene
expression in RAW264.7 cells?
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2.4 Question: Does exposure to BP3 affect the recovery of RAW264.7 macrophages
following a pro-inflammatory signal?
2.5 Question: Does indirect BP3 exposure with secretion factors from 4T1s affect
cytokine gene expression?
2.6 Question: Does BP3 affect the release of proteins from RAW264.7 which can impact
CD4+ T cell activation?
Chapter 3: AIM 2; In this chapter I will discuss the impact of BP3 exposure during
pregnancy and lactation in a p53-/- tumor model. The following questions will be
addressed:
3.1 Question: Does exposure to BP3 during pregnancy and lactation impact the gene
expression related to immune endpoints in a p53-/- tumor model.
3.2 Question: Does exposure to BP3 during pregnancy and lactation impact the
population of GR-1 expressing cells (neutrophils or myeloid derived suppressor cells) in
a p53-/- tumor model?
3.3 Does exposure to BP3 during pregnancy and lactation impact the population of CD31
expressing cells (labeling vascular cells) in a p53-/- tumor model? We anticipated this to
be upregulated because large vessels were increased and IDO1 is associated with
increased angiogenesis
3.4 Does exposure to BP3 during pregnancy and lactation impact the population of CD25
expressing cells (T cells and myeloid tolerogenic cells) in a p53-/- tumor model?
3.5 Does exposure to BP3 during pregnancy and lactation impact the population of
ARG1 expressing cells (M2 polarized macrophages) in a p53-/- tumor model?
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3.6 Does exposure to BP3 during pregnancy alter the number of FoxP3 expressing cells
in tumors of mice implanted with P53 ko epithelium?
Chapter 4: Discussion and Conclusion; In this final chapter I will provide a brief
discussion of the results and provide a conclusion that includes future direction.
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CHAPTER 2
BP3 EFFECT ON A TUMOR CELL LINE AND A MONOCYTE CELL LINE
Macrophages
Macrophages are central regulators of organ development, disease progression,
and tissue growth after an injury occurs (Rehman et al. 2021). There are two origins of
macrophages, tissue-resident macrophages which develop during embryogenesis or
monocyte derived macrophages which originate from bone marrow derived
hematopoietic stem cells (Rehman et al. 2021).
Macrophages are one of the first cells to activate in response to inflammation. The
monocytes and macrophages respond to chemokines through specific receptors on their
membranes. The chemokines help them traffic to areas of concern. They function as an
alert system during a microbial invasion and are essential in adaptive immune responses
(Shi & Pamer, 2011). The structure of a macrophage resembles an amoeba so they are
readily able to move and phagocytose dying cells and foreign bodies (Rehman et al.
2021). The digested proteins are then displayed on the cell surface in the context of the
major histocompatibility complex. This antigen presentation allows for determination by
adaptive immune cells as to whether an attack should be mounted or the proteins are
“self” antigens and should be ignored (Jakubzick et al. 2017).
In addition to presenting an antigen, macrophages also secrete cytokines (i.e.
TNFα, IL6 and IL-1b) and other chemokines (i.e. CCL2, CCL3, CXCL12) in this initial
inflammatory response. Once the T helper cells are called to the area they are able to
activate cytotoxic T cells and others in order to fight against the infection (Jakubzick et
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al. 2017). From this point the T cell can also call in B cells to secrete antibodies which
can target cells presenting the antigen in the future (Shi & Pamer, 2011).
Plasticity of macrophages
Macrophages exhibit plasticity and can be polarized towards 3 overarching
phenotypic and behavior categories, M0, M1, and M2. These categories are different
endpoints on a spectrum. However, it is important to note that it is a spectrum and the
macrophage can also present a hybrid phenotype (Rehman et al. 2021). M1 macrophages
are categorized as proinflammatory. These macrophages have enhanced antigen
presenting capabilities, produce an abundance of reactive oxygen intermediates, and rely
on anaerobic glycolysis for energy metabolism (Rehman et al. 2021). Interferon-gamma,
a Th1 cytokine, lipoproteins, and intracellular pathogens all promote M1 differentiation
(Roszer, 2015). Once polarized towards this phenotype they are able to generate Nitric
Oxide from L-arginine via iNOS activity (Rehman et al. 2021).
They also secrete important proinflammatory cytokines including IL-1beta,
TNFα, IL-12, IL-18, and IL-23 to direct the activity of other immune cell types towards
the best function to clear the problem. M2 macrophages can be divided into
subcategories of M2a, M2b, and M2c, and M2d each exhibiting their own activation
markers. Polarization towards the classic M2a phenotype is achieved through exposure to
Th2 cell cytokines IL-4, and IL-13. M2b polarization is achieved through exposure to
LPS together with these cytokines. M2c polarization results from exposure to IL4 and
IL13 together with glucocorticoids and TGF-beta. Finally, macrophages are polarized
towards the M2d phenotype when adenosines and IL6 are also present.
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M2a macrophages are important for wound healing and tissue repair via initiation
of collagen synthesis and cell movement (Rehman et al. 2021). M2c macrophages are
important for resolution of inflammation. They produce IL-10 and TGF-beta which are
able to further increase macrophage differentiation towards the M2 phenotype and
suppress T cell activity.
Macrophages and tumors
Although M2 can be beneficial for pathogen defense, mitigating inflammatory
responses, and promoting wound healing, but they are also known to be involved in more
nefarious health/ disease presentation such as aiding in allergic inflammation, tumor
growth, and play a role in endocrine signaling (Roszer, 2015). Tumor and stromal derived
factors from the tumor microenvironment (TME) divert macrophages towards yet another
phenotype which is similar, but distinct from M2 macrophages (Williams et al. 2016).
The tumor associated macrophage (TAM) behaviors are manipulated to support tumor
growth and metastasis (Williams et al. 2016). They promote cancer cell intravasation and
together with fibroblasts promote cleaving of the extracellular matrix which is essential
for cancer cells to have a path to promote tumor growth and the development of new
blood vessels, known as angiogenesis, which is a prerequisite for metastatic disease.
Macrophages function to promote tight intercellular junctions with endothelial
cells, and also provide survival cues to these endothelial cells. TAMs facilitate metastasis
by reorganizing the extracellular matrix and degrading the basement membrane. This
allows for tumor cell extravasation. During metastasis TAMS are observed to directly
interact with tumor cells (Majidpoor & Mortezaee, 2021), an association that is
encouraged through production of chemo-attractants such as CSF1, CCL2, CCL3,
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CXCL12, VEGF, and SEMA3a. An upregulation of CCL2 is correlated with tumor
vascularization, when blood vessels invade tumors.
Chemokines
Signals released from monocytes, macrophages and dendritic cells are responsible
for trafficking and the activity of other immune cells. Immune cells communicate via
cell-to-cell contact or secreted signaling molecules. Cytokines are proteins important for
immune cell activation and function. Chemokines are ligands for CC motif- or beta
chemokine receptors. A CC chemokine has two cysteines (amino acids) adjacent to the
amino terminus and are crucial for the rapid response and specific chemotaxis of the
cells. Chemokines can show both anti-cancer and pro-cancer properties (NIH, 2021).
Specific chemokines of interest to this thesis are CCL2, CCL3, and CCL4.
CCL2 is one of the key chemokines regulating migration and infiltration of
macrophages. CCL2 is produced by many cell types (Fujimura 2015), such as
endothelial, fibroblasts, epithelial, smooth muscle, mesangial, astrocytic, monocytic, and
microglial cells. The main source of CCL2 however is macrophages (Fujimura 2015).
The receptor for CCL2, CCR2, is mainly expressed in hemopoietic cells, monocytes, and
a small population of T cells. In humans, CCR2 is highly expressed in chronic
inflammatory diseases, such as arthritis or kidney disease. This is similar in mice, where
CCR2-positive T cells accumulate after an inflammatory stimulus (Mack 2001).
CCL2 recruits and activates pro-tumor macrophages although its effect is
mediated by neutrophils and macrophages (Lavender, 2017). The actions of CCL2 can
vary depending on the presence of TGF-B signaling (Fridlender, 2009). It is also
triggered by exposure to IL-4 and IFNγ (Gschwandtner, 2019). The CCL2 crosstalk
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between macrophages and breast cancer cells is also believed to increase the breast
cancer stem like activity. (Zhang 2021). An in vivo mechanistic study in mice, found that
a CCL2 triggered chemokine cascade promoted the metastatic seeding of breast cancer
cells (Kitamura, 2015). The CCL2 amplified and activated inflammatory macrophages to
produce more CCL3, which facilitated the macrophage interaction with the breast cancer
cells.
CCL3 has the ability to activate both innate and adaptive immune responses.
CCL3 binds to CCR1, CCR3, and CCR5 which are expressed in immature myeloid cells,
neutrophils, eosinophils, T cells, and monocytes among other cell types. In vitro studies
have also revealed that CCL3 secretion induces chemotaxis of CCR1 and CCR5
expressing cells (Rabin 2003). Interestingly CCL3 plays a large role in the mobilization
of myeloid precursor cells and is able to stimulate mature myeloid precursor cells as well.
CCL3 works to sustain the recruitment of cells during an inflammatory response
(Schaller, 2018). There is conflicting data on how CCL3 affects tumors. In several
studies, CCL3 was found to reduce tumorgenicity and extend survival (Schaller, 2018),
however, in other mouse studies CCL3 has contributed to cancer growth (Kitamura,
2015).
CCL3 is produced in humans and mice by various cell types, including Tregs, T
cells, macrophages and some cancer cell types (Wang, 2013). Increased CCL3 expression
was found to be higher in basal-like invasive human breast carcinoma associated with
poor prognosis (Kitamura, 2015).
CCL4 is a macrophage inflammatory protein that induces the recruitment of
dendritic cells, neutrophils, monocytes, macrophages, and T cells, including T regulatory

19

cells to inflammatory sites. It also acts on CD4+ T cells. The primary receptor for CCL4
is CCR5 and serves as a chemoattractant for CCR5 expressing cells. The expression of
CCR5 and CCR1 on T cells suggest that CCL3 and CCL4 may play a role in cellmediated immunity (Rabin 2003).
In addition, tissue environment plays a critical role in activating macrophages
towards M2. Conditioned media as well as cell to cell interactions can determine the level
of M2 markers and there are also tissue-derived endocrine signals that have the potential
to promote M2 activation regardless of the IL-4/STAT6 receptor pathway.
Macrophages and breast development
Macrophages serve various functions in different endocrine organs of the body.
Macrophage-endocrine cell interactions determine the function of endocrine tissues
through the hypothalamus-pituitary-thyroid axis (Rehman et al. 2021). The breast is a
central location where hormones can impact macrophage function. In mammary
development, macrophages are recruited during ductal structure growth in the mammary
glands. They play an important role in tissue patterning, branching morphogenesis, and
regulate vascular growth(Lin et al., 2002). They also help guide the fusion of endothelial
cells which is necessary for vascular sprouting (Qui et al. 2018). By producing matrix
metalloproteinases (MMP), macrophages assist in the remodeling of the extracellular
matrix during the outgrowth of ductal structures(Qui et al. 2018). Macrophages that
reside in the tissue of the mammary gland maintain the viability and function of
mammary stem cells (Gyorki et al. 2009: Williams et al. 2016). These tissue-resident
macrophages are maintained and proliferate due to a colony stimulating factor (CSF1)
produced in the local tissue stroma, which is a key growth factor that dictates
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macrophages proliferation and survival (Williams et al. 2016). These macrophages are
indefinitely replenished by the continued recruitment of circulating monocytes.
A surplus of macrophages in breast cancer is generally associated with decreased
overall survival and is an independent prognostic indicator of breast cancer (Majidpoor &
Mortezaee, 2021). Additionally, chronic inflammation develops when the body is unable
to regulate immunostimulatory signals and they are left activated for a prolonged period
of time. Low levels of reactive oxygen species, which aren’t enough to cause death may
lead to increased mutagenesis if DNA repair pathways are compromised. During these
periods of high inflammation macrophages can undergo apoptosis in order to suppress
persistent immunity and facilitate wound healing. However, this can also in turn support
tumor growth by facilitating angiogenesis and showing trophic macrophage
characteristics. When macrophages are exposed to poorly vascularized tumor regions,
HIF1a and HIF2a are upregulated to provide metabolic adaptation in a poor oxygen
environment and further an immunosuppressive environment. The production of IDO1 by
macrophages represents an inflammatory induced response which in turn suppresses T
cell activity.
The body requires different immune responses in order to adapt to its exposures to
disease (Olsen, 1996). Inflammatory responses could benefit during an infection but if
prolonged could increase likelihood of autoimmune diseases (Olsen, 1996). In women
this is more common than in men (Olsen, 1996). This suggests that changes to female sex
hormones play a role in chronic inflammatory diseases and periods of vulnerability such
as menopause, when estrogen levels lower, wearing off its anti-inflammatory effect
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which in turn can leave a woman more susceptible to chronic inflammation (Olsen,
1996).
Specifically in breast cancer, elevated body mass index (BMI) during menopause
increases the risk of developing hormone receptor-positive breast cancer (Qiu et al.
2018). These overweight conditions contribute to chronic inflammation in the mammary
tissue even if there is no cancer present. When examining these fatty tissues they have
been found to contain macrophage-associated inflammatory pathways, including IL6, IL8, CCR5, and PPARa (Qiu et al. 2018). In these dysfunctional adipose tissues known as,
adipocyte hypertrophy, macrophages are recruited due to an abundance of apoptoticinduced cell death and establish inflammatory foci called, crown-like structures (CLS).
This results in the release of free fatty acids that stimulate macrophages and lead to an
upregulation of TNFα, IL1β, IL6, COX2, and PGE2 (Qiu et al. 2018). This can lead to an
upregulation of CYP19, which is a gene that can induce estrogen production (Qiu et al.
2018) creating a positive feedback loop where chronic inflammation is sustained.
Endocrine Disrupting Chemicals (EDCs) and macrophage interactions
Environmental estrogens are ubiquitous worldwide including the arctic leading to
unavoidable exposure (Chighizola, 2012). Environmental estrogens can be found in
plants, fungi, meat and dairy products, and synthetic chemicals (Chighizola, 2012).
Synthetic chemicals with estrogenic properties are known as xenoestrogens and are found
in plastics, detergents, pesticides, and industrial chemicals (Chighizola, 2012).
Xenoestrogens are synthetic chemicals that have a diverse group of hydrocarbons
and exhibit estrogen like activity (Chighizola, 2012). Xenoestrogens can vary by having
different numbers of aromatic rings and some can be negatively charged if they are
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chlorinated (Chighizola, 2012). Once xenoestrogens are bound to estrogen receptors, they
are able to translocate the receptor-ligand complex from the cytoplasm to the nucleus,
stimulating the synthesis of estrogen-regulated proteins (Chighizola, 2012). They are also
able to antagonize endogenous hormones and alter the pattern of estrogen synthesis and
metabolism (Chighizola, 2012). It has been proposed that environmental estrogens may
mediate immunologic changes directly by binding to immune cells or indirectly by acting
on several other tissues, modulating cytokine production (Chighizola, 2012).
Many studies examining hormone or xenoestrogens utilize a mouse macrophage
cell line called RAW264.7. In RAW264.7 E2 treatment suppressed the ability of LPS to
cause pro-inflammatory M1 polarization, inhibiting nitrite production and TNFα
secretion (Kim, 2003: Tomaszewska, 2003). Pregnancy levels of E2 inhibit
proinflammatory pathways such as, TNFα, IL-1b, and IL6 in M0 and dendritic cells
while stimulating cytokines including IL-10 in M0 and dendritic cells(Straub, 2007).
Using RAW 264.7 cells stimulated with LPS, a select group of 21 endocrine disrupting
chemicals were analyzed to determine their immunologic and cytotoxic effects (Kim,
2015). Some key endocrine disrupting chemicals were fenitrothion (FTH), pthlatates,
estriol, estradiol, and phenols (Kim, 2015). Fenitrothion is a common insecticide that
inhibited mRNA expression of iNOS which reduced NO production. Additionally,
pthlatates and estriol also reduced NO production but this was not dependent on iNOS
expression (Kim, 2015). In contrast, benzo(a)pyrene, a hydrocarbon produced during
combustion, increased NO in RAW264.7 cells (Kim, 2015). The chemicals studied
altered macrophage function in a dose dependent manner (Kim, 2015).
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Immune cells undergo death through apoptosis or necrosis. Necrosis can induce
inflammation while apoptosis can induce a tolerogenic response (Kim, 2015). When
RAW264.7 cells were treated with estradiol or phenol, there was an increase in apoptosis
(Kim, 2015). Benzo(a)pyrene caused an increase in cell death that was independent of
apoptosis (Kim, 2015). These results exemplify that effects of estrogenic EDCs on
macrophages may be greatly diverse depending on the nature of the chemicals (Kim,
2015).
BPA and macrophages
Although BP3 is not as extensively studied as BPA, studies regarding this
endocrine disrupting chemical emphasizes the need to evaluate potential adverse immune
effects that could be associated with BP3. Here I discuss adverse effects of BPA relating
specifically to macrophages which further prompts the need to expand on BP3 studies to
provide a comprehensive assessment of its effects on the innate immune system.
As a common chemical used in plastics, BPA has been extensively studied and
shown to cause adverse immune effects, particularly involving macrophages. BPA has
been shown to aggravate atherosclerosis, a cardiovascular disease (Sui et al. 2018).
Macrophages are known to play a critical role in the development of atherosclerosis.
Mice that were chronically exposed to BPA through drinking water led to enhanced
production of inflammatory cytokines and macrophage infiltration. The macrophages
isolated from the BPA exposed mice demonstrated a pro-inflammatory phenotype and
impaired DNA-repair capacity. The DNA repair play critical for BPA enhancement of
macrophage inflammation and atherosclerosis involved sirtuin I (Yang et al. 2021).
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In addition to DNA repair mechanisms that impact BPA’s inflammatory effect,
dysregulation of non-coding RNAs (LncRNAs) can change gene expression and
influence the cross-talk between signaling pathways through network gene interactions
which leads to adverse macrophage effects. The study analyzed red common carp, an
aquatic species, HK macrophages and found the pro-inflammatory cytokine, IL1β to be
significantly upregulated. Analysis of pathways suggested that BPA used NF-kB, TLR,
HIPPO, and MAPK signaling pathways to cause the dysregulation and adverse immune
responses in the primary HK macrophages (Liu et al. 2020).
BPA can induce the production of cytokines by instigating an immune response.
Using mouse spleen and thymus cells in vitro, BPA, stimulated macrophages to secrete
various cytokines including, IL-1, IL6, IL-12, TNFα, and MCP-1 (Yamashita, 2005).
This was also seen using THP-1s, a human macrophage cell line. BPA increased the
expression of pro-inflammatory cytokines, TNFα and IL6 while decreasing the
expression of anti-inflammatory cytokines, including TGF-b and IL-10 (Liu, 2014). It
was found that this occurs through an estrogen-receptor (alpha and beta) dependent
mechanism. This evidence suggesting that BPA stimulates a pro-inflammatory response
prompts the need to investigate whether BP3, an endocrine disrupting chemical that is
also capable of mimicking estrogen, has adverse effects on macrophages as well.
Results
2.1 Question: Does a direct exposure to BP3 alter anchorage independent growth or
stem like gene expression in 4T1 cells? Does BP3 enhance the secretion of factors
from macrophages that facilitate anchorage independent growth of 4T1 cells?
Triple Negative Model
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4T1 murine mammary carcinoma cells are highly tumorigenic, with low
immunogenicity and characteristics that resemble stage IV human mammary gland
tumors (Garcia et al. 2014). When injected into mice, malignant epithelial growth
presents in a solid arrangement and it is known to spontaneously metastasize to other
organs (Garcia et al. 2014). The 4T1 line does not have an estrogen, progesterone, or
epidermal growth factor receptor 2 (ErbB2) protein receptor (Schrors et al. 2020) making
them a model system for mimicking humans diagnosed with a triple negative breast
cancer (Schrors et al. 2020). It has been established that the 4T1 mammary carcinoma is
an adequate model of human TNBC in relation to tumor behavior and potential drug
targeting therapies (Garcia et al. 2014).
Numerous studies have suggested that estrogenic EDCs can drive the proliferation
of ERa positive breast cancer cell lines (Shanle & Wu, 2011). The Jerry lab has
demonstrated that BP3 in particular has a weak estrogenic effect on T47D cells. Triple
negative breast cancer is particularly difficult to treat because it does not exhibit
expression of any of the standard receptors which can be targeted (ER, PR, Her-2). We
are interested in whether BP3 could impart pro-tumorigenic activity on triple negative
breast cancer lines through its interaction with stromal cells and crosstalk with the breast
cancer cell line.
To accomplish the overall goal I first needed to establish whether BP3 could
affect growth or migration through an ER independent direct effect on the cells. 4T1
cells, were treated with increasing doses of BP3 or the vehicle DMSO and the number of
viable cells were assessed using an MTS assay.
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We found that there is no change in migration when 4T1s are treated with BP3 at
10 or 30uM for 48 hours. There was also no change in proliferation after 48 hours when
4T1s were treated at varying doses, 0.3,1,3,10,30uM (Figure 1f).
To determine whether BP3 could impact the migration of cells, I utilized scratch
wound assays. Cells were plated and allowed to grow to confluence. A pipet tip was used
to scratch a void through the cells. The ability of cells to migrate back across the void
was monitored via microscopy over time on the 8th and 24th hour of cell growth. The
width of the scratch was measured using image J and graphed. We found that the scratch
closed at rates similar to the DMSO control treated cells suggesting that BP3 did not
affect migration (Figure 1g).
To determine whether BP3 exposure could alter gene expression. 4T1 cells were
treated with 30uM BP3 or DMSO (vehicle) for 48 hrs. The cells were lysed in Trizol and
the RNA purified. PCR was performed using Agilent’s Brilliant III ultrafast QRTPCR kit
to examine the impact of BP3 exposure using primers specific to chemokines, chemokine
receptors, growth factors, cytokines as well as genes associated with stemness or EMT.
We found that among chemokines Ccl2, Ccl3, Ccl4, Ccl5, and CCL22, CCL2
expression is significantly induced 4T1s treated with BP3 (Figure 1a). We also followed
this up by examining the expression of their corresponding chemokine receptors,
including, Ccr1, Ccr3, Ccr4, and Ccr5 (Figure 1b). We found that there is no change in
expression between the control and exposed group (Figure 1). IL1β is a key cytokine in
the immune environment. It can be expressed by tumor cells as well as macrophages and
typically facilitates tumor growth. When analyzing its expression we found that BP3
decreases IL1β expression (Figure 1d).
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We also examined expression of a several genes encoding secreted protein
important for regulating immune function TGFβ1, an immune suppressive growth factor
important in development,Cox2, an inflammatory related gene and IL6 , a cytokine
released from tumor cells and macrophages. TGFβ and Cox-2 were not significantly
affected following BP3 exposure whereas Il6 demonstrated inconsistent results (Figure
1d).
To determine if BP3 exposure altered the expression of genes involved in cancer
stemness, qRT-PCR was performed to analyze Sox4 and Prom1. Sox4 is a transcription
factor that regulates survival, differentiation and epithelial to mesenchymal transition.
Prom1 is a transmembrane glycoprotein that inhibits differentiation of stem cells (Figure
1e). CDH1, an adhesion related protein. It is downregulated when epithelial cells
transition into more migratory cells (Figure 1e). We did not observe a significant change
in mRNA expression of any of these genes following exposure to BP3, however slight
trends up in Prom1 and Sox4 were of interest (Figure 1e.
Based on these interesting trends in cytokine RNA expression, we collected
conditioned media off of 4T1 cells treated with BP3 and examined the level of secreted
proteins using a Mesoscale Discovery pro-inflammatory protein analysis panel (MSD).
We found that protein expression of KC/GRO, a neutrophil chemoattractant, is
significantly decreased in the BP3 exposed 4T1 cells, however there is no change in IL6
protein expression, which agrees with the gene expression analysis (Figure 1i). These
results suggest that the behavior (proliferation and migration) of the ER negative 4T1
tumor cells are largely unaffected by direct exposure to 30uM BP3. However, CCL2
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RNA appears to be upregulated and KC/GRO is decreased following BP3 exposure in an
ER independent manner.
2.2 Question: Does a direct exposure to BP3 alter anchorage independent growth or
stem-like gene expression in 4T1 cells? Does BP3 enhance the secretion of factors
from macrophages that facilitate anchorage independent growth of 4T1 cells?
The ability of normal epithelial or tumor cells to survive and grow anchorage
independently is a marker of stem-like behavior. One can enrich populations of stem-like
or cancer stem-like cells by growing them in conditions where they can’t form good
interactions with the plastic tissue culture dish (anchorage independent growth). In
tumors, this behavior is a marker for an aggressive cell death resistant characteristic.
Since there was a trend towards elevated Sox4 and Prom1 mRNA expression following
4T1 exposure to BP3, we investigated whether BP3 affects 4T1 anchorage independent
growth.
We plated 4T1 cells at a low density on low attachment cell culture plates and
looked for growth of primary and secondary colonies. 4T1s were plated as single cells
and cultured for 1 week. After 1 week the cells, now in colonies, were resuspended and
re-plated in the same treatment groups for another week. After week 2 colonies were
measured and any colony above 40um was quantified in each treatment group.
We found that both 4T1s treated with BP3 through direct treatment and 4T1
conditioned media showed a decreasing trend in secondary colony growth (Figure 1c).
This was not what we expected given the upwards trend of Prom1 and Sox4, but it was
still interesting.
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Since macrophages can secrete factors that can facilitate the cancer stem-like activities in
breast cancer we also asked whether exposure of the RAW264.7 macrophage cell line to
BP3 could result in the secretion of factors that would in turn enhance anchorage
independent growth of tumor cells. We set up an anchorage independent assay where
4T1s were treated with varying conditioned medias containing macrophage secreted
proteins. The 4T1s treated with M0 conditioned media demonstrated a significant
increase the ability to grow anchorage independently and then form secondary colonies
(Figure 2g). This suggests that BP3 causes macrophages to secrete factors that can in turn
alter 4T1 behavior towards more stem-like growth/survival abilities.
2.3 Question: Does BP3 alter the cytokine or chemokine expression of the RAW
264.7 macrophage cell line? Does BP3 affect polarization in the absence of other
signals? Does it alter LPS induced pro-inflammatory activity? Does BP3 affect
tumor associated gene expression in RAW264.7 cells?
Monocyte Model Raw 264.7
The RAW264.7 cell line is an immortalized monocyte/macrophage-like that
originates from an Abelson leukemia virus (MuLV) transformed cell line from male
Balb/C mice (Taciak et al. 2018). They are a traditional model when studying
macrophages and are able to be manipulated to express a more M1 phenotype (Taciak et
al. 2018). Upon LPS stimulation, RAW 264.7 cells display an M1 phenotype and when
co-cultured with 4T1 cells they exhibit the phenotype of tumor associated macrophages
(TAMs) (Kong et al. 2019). The RAW264.7 cell line is unique because its phenotype can
change depending on its passage or micro-environment (Kong et al. 2019).
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To examine gene expression of the RAW264.7 cells the M0 cells were treated
with DMSO (control) or 30uM BP3 for 48 hours. Once the cells were lysed in Trizol and
the RNA purified, PCR was performed using Agilent’s Brilliant III ultrafast QRTPCR
kit. We then analyzed gene expression and determined statistical significance using
Graphpad Prism.
Among the chemokines examined (Ccl2, Ccl3, Ccl4, Ccl5, and Ccl22) Ccl2 has an
increasing trend in gene expression (Figure 2a). Interestingly there is contradicting results
in CCL4 expression. This is consistent with a decrease in Ccl4 noted in lungs of animals
exposed to high levels of BP3. However, the results were not always consistent from one
experiment to another. Among one set of samples, Ccl4 appears to have a slight
increasing trend, and in another set of samples there was a significant decrease in Ccl4
gene expression. Among their corresponding receptors, Ccr1,Ccr2,Ccr3,Ccr4, and Ccr5,
Ccr1 shows an increasing trend and CCR2 shows a decreasing trend, but there was no
change in expression amongst Ccr3,Ccr4, or Ccr5 (Figure 2b).
ARG1 expression was examined because it has been shown to function as a tumor
suppressor in breast cancer and we wanted to determine if BP3 altered its expression in
immortal monocyte cells (Figure 2c). BP3 appeared to decrease expression compared to
the vehicle group. Additionally to determine whether BP3 altered macrophage function,
we examined Mrc1 expression (Figure 2c). This gene codes for a protein that mediates
the endocytosis of glycoproteins by macrophages. We found that BP3 increases Mrc1
expression in RAW264.7 cells.
IL10 is an anti-inflammatory cytokine and our results show a minimal decrease in
Il10 expression in the BP3 exposed cells (Figure 2c). We found no change in IL6
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expression and a non-significant increase in expression in Mrc1. To further determine if
BP3 impacts the gene expression of immune related cytokines we examined IL1β and
TNFα expression and found no change (Figure 2d).
Based on these interesting trends in cytokine RNA expression, we collected
conditioned media off of RAW 264.7 cells exposed to BP3 and examined the level of
secreted proteins using a Mesoscale Discovery pro-inflammatory protein analysis panel
(MSD).
At the protein level we also found no change in IL1β, IL6, IL-10, or TNFα
expression (Figure 2e and 2f). The MSD showed high expression levels of IL6, IL-10,
and TNFα in both treatment groups. Additionally the pro-inflammatory cytokine IL12p70
showed no change in expression (Figure 2e). These results are interesting because BP3
may be enhancing the immune response of RAW264.7 cells. This lead us to wonder how
BP3 may effect RAW 264.7 cells stimulated with LPS.
M1
By treating RAW264.7 cells with LPS, macrophages were polarized towards the
M1 phenotype. First we wanted to determine whether BP3 affected M1 proliferation.
Using an MTS assay we determined that there is no change in proliferation of M1
macrophages when treated with varying doses of BP3, 0.3uM, 3uM, and 30uM, for 48
hours.
Following this, to examine gene expression of the RAW 264.7 cells stimulated
with LPS, cells were exposed to DMSO (control) or 30uM BP3 for 48 hours. Once the
cells were lysed in Trizol and the RNA purified, PCR was performed using Agilent’s
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Brilliant III ultrafast QRTPCR kit. We then analyzed gene expression and determined
statistical significance using Graphpad Prism.
We examined inflammatory genes and found that there is no change in Il6
expression, however TNFα, IL1β, and Cox2 show an increase in gene expression (Figure
4b). These changes in expression were not seen in the analysis of M0 expression and this
increase in expression could indicate that BP3 is increasing the inflammatory response of
phenotypic M1 macrophages in way that M0 cells are not, indicating that LPS is
activating an immune response.
Based on these interesting trends in cytokine RNA expression, we collected
conditioned media off of M1 cells treated with BP3 and examined the level of secreted
proteins using a Mesoscale Discovery pro-inflammatory protein analysis panel (MSD).
There is high IL6 expression in both treatment groups, although BP3 appears to
decrease IL6 expression after 48 hours and less so after 72 hours (Figure 5c). IL10 is less
expressed in the M1 conditioned media compared to the M0 conditioned media and it
appears that BP3 may slightly decrease IL10 expression at 48 hours, however there is no
change at 72 hours (Figure 5d). There is no change in IL12p70 expression at 48 and 72
hours (Figure 5d). Additionally we found that, there is high TNFα expression in both
treatment groups, although BP3 appears to increase TNFα expression after 72 hours
however this is not apparent at 48 hours (Figure 5c). This may indicate that the cells
changed their protein secretion after being exposed to BP3 for an additional 24 hours.
These results indicate that BP3 could be upregulating TNFα, IL1β, and Cox2.
This change was not observed in IL6 gene expression. When looking at secreted protein
expression via MSD it is evident that BP3 increases TNFα protein expression at 72 hours
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(Figure 5c). As expected from the lack of change in IL6 gene expression there was also
no change in secreted protein expression of IL6. Interestingly, the protein expression of
IL1β was not upregulated as was seen in the RNA expression (Figure 5c).
TAMs
We sought to determine whether BP3 treatment of RAW 264.7 altered
polarization when co-cultured with 4T1 cells. We found that BP3 altered the polarization
of RAW macrophages towards TAMs after co-incubation with tumor cells from the 4T1
cell line. TAMs have been shown to support tumor growth and to promote angiogenesis
(Majidpoor & Mortezaee, 2021). Previous studies showed TAMs upregulating CCL2
which may lead to an increase in tumor vascularization (Majidpoor & Mortezaee, 2021).
To determine the effect of BP3 on these TAM cells we analyzed their gene
expression. The Raw 264.7 cells co-cultured with 4T1s were treated with DMSO
(control) or 30uM BP3 for 48 hours. Once the cells were lysed in Trizol and the RNA
purified, PCR was performed using Agilent’s Brilliant III ultrafast QRTPCR kit. We then
analyzed gene expression and determined statistical significance using Graphpad Prism.
We found that Ccl2 and Ccl3 gene expression slightly decreases when Raw264.7
cells are co-cultured with 4T1s for 48 hours (Figure 3a). Ccl5 had a significant decrease
in gene expression. In addition, Ccl4 appears to increase slightly. Corresponding
chemokine receptors, Ccr1 and Ccr4 showed a decrease in gene expression. There is no
change in gene expression of Ccr2 or Ccr3 (Figure 3b).
In order to look at Ccl2 gene expression over time, TAMs were cultured for 24,
48, 72, and 96 hours. At the 24, 48, and 96 hour time points, Ccl2 demonstrated a
decrease in expression which was significant at 96 hours (Figure 3c). However,
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interestingly at the 48 hour time point there is a trending increase in expression which
contradicts the slight decrease seen in previous qRT-PCR results.
When examining inflammatory genes, Il6 and Il10 gene expression increases
slightly, while CD163 expression decreases (Figure 3d). In addition, Mrc1 and ARG1
gene expression decreases and there is no change in iNos expression (Figure 3e). iNos is
an important gene that enables nitric oxide production and can lead to tumor promotion
or death depending on its origin (Prerrota et al. 2018).
We then wanted to examine whether TAM conditioned media with DMSO or BP3
would impact 4T1 anchorage independent growth because TAMs have been shown to
support tumor growth and BP3 may alter these effects. We plated 4T1 cells at a low
density on low attachment cell culture plates and looked for growth of primary and
secondary colonies. 4T1s were plated as single cells and cultured for 1 week. After 1
week the cells, now in colonies, were resuspended and re-plated in the same treatment
groups for another week. After week 2 colonies were measured and any colony above
40um was quantified in each treatment group. The anchorage independent assay showed
an increase in secondary colonies (Figure 3f).
Based on these interesting trend in cytokine RNA expression, we collected
conditioned media off of TAM cells treated with BP3 and examined the level of secreted
proteins using a Mesoscale Discovery pro-inflammatory protein analysis panel (MSD).
We found that There is a decrease in IL6 expression although it is not significant.
There is high KC/Gro expression in both treatment groups although there is no BP3
dependent effect of KC/Gro protein expression in TAMs conditioned media (Figure 3g).
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Additionally, when looking at inflammatory protein expression we found that there is no
BP3 dependent effect on IL10, IL12p70, or TNFα expression (Figure 3e and 3f).
These results are indicative that TAMs exposed to BP3 may be stimulating 4T1
anchorage independent growth. BP3 could also be inhibiting TAM upregulation of
CCL2, CCL3, and CCL5. The lack of protein changes shows that BP3 is not triggering an
immune response that alters the protein levels of IL10, IL12p70, or TNFα, but may be
triggering an immune response through IL6.
2.4 Question: Does exposure to BP3 affect the recovery of RAW264.7 macrophages
following a pro-inflammatory signal?
The recovery phase of Raw 264.7 is important to consider because BP3 is
excreted regularly in humans and it has the potential to cause changes to macrophage
behavior even when it is no longer present. We explored the recovery period M1
macrophages by treating them with DMSO or BP3 for 48 hours and then replacing the
media with fresh untreated RPMI media for varying time periods. As a control we
measured proliferation after the 48 hour time period and saw no change which is
consistent with previous data. Interestingly, during the 24 hour period of M1 recovery
proliferation increases at 0.3uM and more so at 30uM. At 3uM there is a slight decrease
in proliferation. When looking further at the difference between live and dead cells at 24
hours of recovery there is no change, however at the 72 hour period there is no change in
the number of live cells but there is a significant increase in the number of dead cells in
the BP3 treated group.
Following this, we examined gene expression by isolating and purifying the RNA
and PCR was performed using Agilent’s Brilliant III ultrafast QRTPCR kit. We then
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analyzed gene expression and determined statistical significance using Graphpad Prism.
When examining the recovery phase of M1, the gene expression analysis showed that
BP3 was found to reduce IL1β, IL6 and TNFα during LPS activation (Figure 5d). It does
not appear to affect the resolution of the protein levels except for TNFα which appears to
be elevated for longer. This suggests that BP3 may affect the metabolic activity. In
particular this may relate to mitochondrial succinate dehydrogenase.
2.5 Question: Does indirect BP3 exposure with secretion factors from 4T1s affect
cytokine gene expression?
We were interested in how Raw 264.7 would respond to exposure of BP3 through
4T1 conditioned media. This would lead to an indirect exposure and would answer
whether the secreted factors of 4T1s exposed to BP3 could alter Raw 264.7 gene
expression.
Raw cells were treated with 4T1 conditioned media DMSO (vehicle) or BP3 for
48 hours. We examined gene expression by isolating and purifying the RNA and PCR
was performed using Agilent’s Brilliant III ultrafast QRTPCR kit. We then analyzed gene
expression and determined statistical significance using Graphpad Prism.
We found that CCL2 expression decreased in the Raw264.7 cells exposed to BP3
and 4T1 secreted factors. Additionally CCL3 and iNOS appear to have an increase in
expression. We found no change in IL6 expression. These changes is chemokine
expression indicate that indirect exposure to BP3 through 4T1 conditioned media could
be altering the immune response of Raw 264.7 cells (Figure 6).
2.6 Question: Does BP3 affect the release of proteins from RAW264.7 which can
impact CD4+ T cell activation?
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We were interested in whether BP3 affected the release of proteins from Raw
264.7 cells which in turn could impact CD4+ T cell activation. Macrophage and T cell
interactions are essential to coordinating appropriate immune responses. In particular
these CD4+ T cells can be divided into TH1 and TH2 cells. We wanted to determine
whether Raw 264.7 secreted factors exposed to BP3 altered the activation of CD4+ T
cells.
T cells were treated with direct DMSO or 7.5uM BP3 for 48 hours or Raw (M0)
conditioned media for 48 hours. The control direct treatment of DMSO or 30uM BP3
showed a significant decrease in total cells and a decrease in live cells. This is consistent
with unpublished data from Stephanie Morin. The T cells treated with Raw CM had a
decrease in total cells in the BP3 group but no change in live cells. Interestingly, both
directly treated T cells and T cells treated with Raw CM show BP3 significantly
decreasing the number of dead cells.
Following this, gene expression was quantified by by isolating and purifying the
RNA and PCR was performed using Agilent’s Brilliant III ultrafast QRTPCR kit. We
then analyzed gene expression and determined statistical significance using Graphpad
Prism. In the control group there was an increase in gene expression of IL4 and IFNγ,
Additionally, we saw a significant decrease in TGFβ1 and IL2 expression.
We also exposed T cells to TAMs conditioned media and gene expression
analysis showed a decrease in IL4 expression and no change in IFNγ gene expression.
The T cells treated with TAMs CM had no change in gene expression of TGFβ1 or IL2
expression between TAMs CM DMSO and TAMs CM BP3 (Figure 7f).
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We also wanted to look at protein expression. We collected conditioned media off
of the T cells and examined the level of secreted proteins using a Mesoscale Discovery
pro-inflammatory protein analysis panel (MSD). This analysis showed significant
decreases in IFNγ, TNFα, IL-4, IL-5, IL6, IL-10, KC/GRO, IL12p70, and IL1β (Figure
7d).
We found that there is a general decrease in cell proliferation following exposure
to conditioned media from BP3 treated RAW but no change in viability (Figure 7a,b,c).
There is also a significant decrease in cytokine secretion. It is unclear whether this was
due to a direct effect or an indirect effect. These results indicate that T cells treated with
M0 conditioned media showed a rescue in cell proliferation but not in cytokine release.
Conclusion
Several studies regarding oxybenzone have shown this chemical to have the
potential of causing adverse immune effects. Although the mechanism of action is
unclear, our research shows that oxybenzone appears to enhance the pro-inflammatory
state of RAW264.7 cells and may result in release of unidentified factors that can impact
4T1 cell anchorage independent cell growth in these pro-inflammatory conditions. BP3
may impact the metabolic activity of recovering RAW264.7 cells following LPS induced
activity, but future work is required. BP3 may impact the release of factors from
macrophages that control T cell activation induced proliferation.
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Figure 1. The effect of 30uM BP3 on 4T1 cell gene and protein expression. (a)
Chemokine gene expression. (b) Chemokine receptor gene expression. (c) Anchorage
independent growth of 4T1s directly and indirectly treated with BP3 (d) Gene
expression of immune markers TGFβ1, IL1β, Cox2, and IL6 (e) Gene expression of
stemness markers CDH1, Sox4, and Prom1 (f) Proliferation of 4T1s treated with
varying concentrations of BP3 (0.3uM, 1uM, 3uM, 10uM, and 30uM). (g) Migration
analysis using a scratch wound assay, at 10uM and 30uM BP3 and microscopy
measurements taken at 8hr and 24hr (h) Migration analysis using a scratch wound
assay. 4T1s were pretreated with BP3 at 10uM and 30uM for 1 hour and then scratch
was made and microscopy measurements taken at 8hr and 24hr (i) Protein expression
of interleukins KC/Gro and IFNΓ.
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Figure 2. The effect of 30uM BP3 on M0 cells (Raw 264.7) gene and protein
expression. (a) Chemokine gene expression. (b) Chemokine receptor gene expression.
(c) Gene expression of Immune markers ARG1, Mrc1, IL10, and IL6 (d) Gene
expression of immune markers IL1β and TNFα. (e) Protein expression of interleukins
IL10 and IL12p70 (f) Protein expression of interleukins TNFα and IL6 (g) Anchorage
independent growth analysis of secondary colonies above 40um in 4T1 cells indirectly
treated with BP3 through M0 conditioned media.

41

Figure 3. The effect of 30uM BP3 on TAMs (Raw 264.7 & 4T1 co-culture) gene and protein
expression. (a) Chemokine gene expression. (b) Chemokine receptor gene expression. (c)
Gene expression of CCL2 over time (24,48,72,and 96 hours). (d) Gene expression of immune
markers. (e) Gene expression of immune markers. (f) Anchorage independent growth analysis
of secondary colonies above 40um in 4T1 cells indirectly treated with BP3 through TAMs
conditioned media. (g) Protein expression measured via ELISA of KC/GRO. (h) Protein
expression measured via ELISA of IL6 and TNFα. (i) Protein expression measured via
ELISA of IL-10, IL12p70, IL1β.
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Figure 4. The effect of 30uM BP3 on Raw 264.7 cells stimulated with LPS
towards M1 phenotype. (a) Proliferation of M1 cells treated with varying doses
of BP3 including, 0.3uM, 3uM, and 30uM. (b) Gene expression of immune
markers IL6, TNFα, IL1β, and Cox2.
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Figure 5. The effect of 30uM BP3 on recovery of RAW264.7 macrophages following a proinflammatory signal. (a) Proliferation of M1 recovering cells at varying doses of BP3
including 0.3uM,3uM, and 30uM measured at 0hr and 24hr via MTS assay. (b) Total
number of live or dead cells during recovery at 0hr, 24hr, and 72hr. (c) Protein expression of
immune markers IL6 and TNFα after 48 or 72 hours of recovery. (d) Protein expression of
immune markers IL-10 and IL12p70 after 48 or 72 hours of recovery.
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Figure 6. The effect of 30uM BP3 on gene
expression of Raw264.7 cells treated with 4T1
conditioned media.
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Figure 7. The effect of 30uM BP3 on T cells directly treated with 30uM BP3 and indirectly
through M0 conditioned media. (a) Total cells after 48hours of direct or indirect treatment of
BP3. (b) Total live cells after 48hours of direct or indirect treatment of BP3. (c) Total dead
cells after 48hours of direct or indirect treatment of BP3. (d) Protein expression of immune
markers IFNγ, TNFα, IL-4, IL-5, IL6, and IL-10. (e) Protein expression of immune markers
KC/Gro, IL12p70, and IL1β. (f) Gene expression of T cells directly treated with 7.5uM BP3
and indirectly treated with BP3 via TAMs conditioned media.
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CHAPTER 3
IMMUNE EFFECT OF BP3 ON A p53-/- TUMOR MODEL
Introduction
The tumor model design consists of Tp53-/- epithelial cells transplanted into
mammary fat pads of BALB/c mice where females were exposed to either 0 (control) or
3000 µg/kg/day oxybenzone throughout pregnancy and lactation. Klara Matouskova
surveilled these mice until they reached 52 weeks of age to investigate tumor latency.
Figure 8 illustrates a schematic created by Klara Matouskova with the study design. The
tumors were taken for analysis of gene expression of several immune related markers.
We found these markers especially interesting because unpublished work has shown that
in mice exposed to BP3 until harvest, these genes were significantly altered.
We chose INos and IL6 to determine whether the tumors showed M1 polarized
macrophages. On the other hand we also explored TGFβ, IL10, and IDO1, as they are
generally immunosuppressive cytokines found in association with Tregs, M2c
macrophages, tolerogenic dendritic cells and MDSC. ARG1 is an important marker for
wound healing and Aldh contributes to the production of retinoic acid, which are
necessary for Tregs. NRP1 is a marker for Tregs. IFNγ and Cox2 are important
inflammatory mediators frequently associated with the upregulation of IDO1. CCL2 is
released by many cell types, including macrophages, and is important for chemoattracting
other CCR2 + cells.
Results
3.1 Question: Does exposure to BP3 during pregnancy and lactation impact the gene
expression related to immune endpoints in a p53-/- tumor model.
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Gene expression from a panel of genes were quantified and included CCL2,
CCL4, NRP-1, ARG1, TGFβ1, TGFβ3, IL4, IL10, ALDH1a1, ALDH1a2, IFNγ, IDO1,
IL6, Cox2, INOS, and IL1β. The results were particularly interesting in regards to IDO
gene expression and GR-1 protein expression. In the following section I will explain how
IDO is involved in the immune system (Figure 9).
3.2 Question: Does exposure to BP3 during pregnancy and lactation impact the gene
expression of IDO1 in a p53-/- tumor model.
Indoleamine 2,3-dioxygenase 1 (IDO1) is a cystolic, monomeric, hemecontaining enzyme that catalyzes the initial rate-limiting step in the degradation of an
amino acid, L-tryptophan using the kynurenine pathway. In addition to this function,
IDO1 can act as a mediator of a signaling pathway that can change the functional
phenotype of specific immune cells, which can be associated with distinct protein
conformations (Pallota et al. 2021). IDO1 is a physiologic checkpoint that can guarantee
homeostasis by modulating immune responses orchestrated by dendritic cells and
macrophages. IDO1 plays a key role in supporting immune privilege including protecting
the fetus from the maternal immune system (Pallota et al. 2021).
There is a strong correlation between IDO1 and immune cell populations
including dendritic cells and T cells (Feng et al. 2020). IDO1 functions as an immune
regulator that has highly regulated catalytic activity as well as nonenzymic functions that
can reprogram the expression profile of immune cells towards a highly
immunoregulatory phenotype (Pallota et al. 2021). There is evidence that IDO1 can tilt
the immune system towards supporting tumors (Prendergast, 2014). IDO1 is an inducible
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enzyme and can be induced by IFNγ (Pallota et al. 2021). Interestingly, TNFα, IL6, and
IL-10 can synergize with each other to increase IDO1 expression (Pallota et al. 2021).
IDO1 resides in the cytosol and can have distinct intra and extracellular topology
depending on the cell microenvironment (Pallota et al. 2021). There is conflicting data
regarding whether elevated IDO1 expression is associated with a better and poor cancer
prognosis (Feng et al. 2020). This may be due to IDO1 expression in both tumor cells and
tumor infiltrating cells which can lead to changes in the tumor microenvironment (TME)
and varying outcomes of tumor prognosis (Feng et al. 2020). IDO1 is expressed in nontumor cells in the TME including, dendritic cells, fibroblasts, endothelial cells,
eosinophils, and macrophages. This correlation between IDO1 and antigen presenting
cells (APCs), including macrophages suggests that APCs could mediate immune
responses via IDO1 (Feng et al. 2020). Additionally, IDO1 can be secreted in
extracellular vesicles, including exosomes (Pallota et al. 2021).
IDO1 has been established as a central driver of malignant development and
progression. It is able to suppress T cells, activate T regulatory cells and myeloid derived
suppressor cells, and further the promotion of tumor angiogenesis (Prendergast, 2014). It
has been implicated in numerous disease including, cancer, chronic viral infection,
allergy, autoimmune, and inflammatory diseases that are categorized by disordered
immune control. It can act on multiple levels to create a favorable environment for tumor
development and metastatic progression (Prendergast, 2014).
Typically, it is activated in the skin and tumor draining lymph nodes as part of the
chronic inflammation required for tumor emergence (Prendergast, 2014). IDO1 is
significantly correlated with tumor mutation burden in breast invasive carcinoma
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(BRCA) and cervical squamous cell carcinoma (CESC) (Feng et al. 2020). IDO1
participates in anti-tumor immune process and is correlated with mutation burden (Feng
et al. 2020). In addition IDO1 drives tumor angiogenesis and metastisis and is capable of
causing angiogenic defect in lungs even in the absence of tumors (Prendergast, 2014).
Studies have shown elevated IDO1 expression on the mRNA and protein level in BrCa
(breast cancer) cells (Heng et al. 2020). IDO1 gene expression in BrCa tissue is
upregulated in triple negative and HER2-enrivhed BrCa subtype when compared to
luminal BrCa, hormone-receptor positive breast cancers, and healthy control tissues
(Heng et al. 2020). IDO1 was highly expressed in triple negative and HER-2 enriched
BrCa subtypes but was absent in luminal BrCa (Heng et al. 2020).
Our results show that BP3 causes an increase in IDO expression. No other genes
showed a significant BP3 dependent effect on expression (Figure 9f)). Following gene
expression analysis our interesting results with IDO expression led us to wonder how
protein markers for cellular subsets may be affected. If so, this might suggest an activity
associated with IDO1 such as angiogenesis, immune suppression involving, Tregs,
tolerogenic DC,M2 macrophages or changes in MDSC/neutrophils. Protein expression
that was quantified via IHC and included GR-1, CD-31, CD25, ARG1, FoxP3 (Figure
10).
3.3 Does exposure to BP3 during pregnancy and lactation impact the population of
CD31 expressing cells (labeling vascular cells) in a p53-/- tumor model?
Endothelial cells play a major role in the control of coagulation, thrombolysis,
vascular tone, permeability, inflammation, tissue repair, and angiogenesis (Pusztaszeri et
al. 2006). Interestingly, endothelial cell molecular characteristics vary in different blood
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vessels and from organ to organ (Pusztaszeri et al. 2006). An important marker for
endothelial cells and angiogenesis is CD31. CD31 is a 130kDa platelet-endothelial cell
adhesion molecule. It also triggers downstream inhibitory signaling upon transhomophilic
CD31 engagement during cell to cell interactions. CD31 signaling is a part of leucocyte
detachment, T-cell activation, platelet activation, and angiogenesis (Liu & Shi, 2012).
CD31 is a constituent of the endothelial intercellular junction, which promote cell-to-cell
adhesion and are required for the organization of blood vessels during embryo
development and tissue proliferation (Pusztaszeri et al. 2006:Dejana et al. 2015).
CD31 plays a major role in the adhesion cascade between endothelial cells during
inflammation and angiogenesis (Pusztaszeri et al. 2006). It is important to note that CD31
expression is not restricted to blood vessels (Pusztaszeri et al. 2006). CD31 is present on
the surface of platelets, monocytes, macrophages, and neutrophils (Pusztaszeri et al.
2006). CD31 loses its expression at intercellular junctions after endothelial cells are
exposed to inflammatory cytokines (Liu & Shi, 2012).
Our results show a decrease in CD31 protein expression suggesting that BP3
decreases the number of vascular cells in the tumor (Figure 10a).
3.4 Does exposure to BP3 during pregnancy alter the number of FoxP3 expressing
cells in tumors of mice implanted with P53 ko epithelium?
The transcription factor forkhead box P3 (FoxP3) is a transcription factor and a
marker for Tregs as an important part of Treg development and function (Zhao et al.
2019). Tregs that are FoxP3+ are suppressors of antitumor responses and maintain
immunological tolerance in host tissues. In general high expression of FoxP3 is thought
to indicate poor prognosis (Shang et al. 2015). Some studies have reported that both
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FoxP3+ T cells and FoxP3+ tumor cells also can promote tumor progression by fostering
angiogenesis. However, there is conflicting evidence indicating that FoxP3+ T cells and
tumor cells could improve survival. It is important to note that FoxP3+ cells are
associated with ER+ cancers (Qian et al. 2017). In addition FoxP3 is also a regulator in
CD4+CD25+ regulatory T cell development and function (Fontenot, 2003).
Our results show no change in FoxP3 protein expression in the tumors exposed to
BP3 (Figure 10b).
3.5 Does exposure to BP3 during pregnancy and lactation impact the population of
ARG1 expressing cells (M2 polarized macrophages) in a p53-/- tumor model?
Increased expression of ARG1 suggests that macrophages are exhibiting M2-like
characteristics. In M2 mouse macrophages arginine is converted to ARG1. Tumorassociated macrophages (TAMs) are also thought to share similar behaviors as the M2
phenotype. Additionally, lactic acid may play a role in polarizing TAMs to a tumor
promoting phenotype that is shown through increased ARG1 expression (Saha et al.
2017).
Our results show no change in ARG1 expression between the vehicle and BP3
exposed mouse tumors (Figure 10c).
3.6 Does exposure to BP3 during pregnancy and lactation impact the population of
GR-1 expressing cells (neutrophils or myeloid derived suppressor cells) in a p53-/tumor model?
GR-1 positive myeloid suppressor cells are thought to suppress the immune
system and promote angiogenesis (Magdalena et al., 2011). They are actively recruited
by various chemokines and are able to produce angiogenic factors including VEGF,
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MMPs, and interleukins (Magdalena et al., 2011). As a result, neovascularization occurs
around tumors and is necessary for tumor growth because of the supply of nutrients and
oxygen (Schmid & Varner, 2010). These myeloid cells are then able to enhance cancer
cell survival. Inflammatory monocytes that are positive for GR-1 have been shown to be
recruited towards pulmonary metastases. GR-1 expression may also be correlated with
CCL2 expression. In tumor cells CCL2 may recruit GR-1+ monocytes to further the
extravasation of the tumor cells (Qian et al. 2012).
Our results show a decrease in GR-1 expression, suggesting that BP3 is
decreasing the number of myeloid derived suppressor cells in the tumor. This could mean
that there is a decrease in MDSC or neutrophils (Figure 10d).
3.7 Does exposure to BP3 during pregnancy and lactation impact the population of
CD25 expressing cells (T cells and myeloid tolerogenic cells) in a p53-/- tumor
model?
CD25+ regulatory T cells are important in maintaining immune tolerance and
immune homeostasis including maintaining the TH1/TH2 balance. (Zhang et al. 2020).
They are also important in the prevention of autoimmunity. CD25 is a subunit of the IL2
receptor and is transiently upregulated during activation of T cells. This in turn activates
IL2 signaling (Shatrova et al. 2016). Infiltrating cells in the tumor have high CD25
expression is associated with poor prognosis. In human cancers CD25 is mainly
expressed in CD4+FoxP3+ T regulatory cells (Song, 2021). CD25+ cells can promote the
secretion of Th2 cytokines and inhibit the release of Th1 cytokines (Zhang et al. 2020).
When mice were exposed to BPA one week before tumor infection, they found
that there was not only an increase in IL4 and IFNγ expression but there was a decrease
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in CD4+CD25+ cells. This shows BPA promoting the development of TH2 cells (Yan et
al. 2008).
Our results show no change in CD25 expression between the vehicle and BP3
exposed mouse tumors (Figure 10e).
Conclusion
Exposure during pregnancy and lactation results in tumors with higher IDO1
expression. This did not appear to correlate with increases gene expression changes of
immunosuppression (IL10 TGFβ, NRP, ALDH or bio markers of cell subsets capable of
suppression (CD25, GR1, FOXP3) however it was associated with significant changes in
angiogenesis. There was a significant elevation of large vessels in these tumors and a
non-significant decrease in micro vessels (CD31). When looking at gene expression of
cytokines and inflammatory factors known to induce IDO1 (IFNΓ IL6 and COX2), we
found no associated elevation suggesting a different route of expression. Future work is
needed to understand the contributing factors and it impact on tumorigenesis.
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Figure 8. The p53-/- mouse model exposed to oxybenzone during pregnancy and
lactation. At 3 weeks of age, female mice were transplanted with Trp53-/- mammary
epithelium. From there they were split into 3 treatment groups by 6 weeks of age.
These included parous oxybenzone, parous controls, and virgin controls. For this
thesis, we will focus only on the parous treatment groups. During pregnancy and
lactation the mice received either 0 (control) or 3000 µg/kg/day oxybenzone orally.
The mice were surveilled throughout adulthood and involution where at 52 weeks the
mice were euthanized and tissue was collected for analysis.
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Figure 9. Gene expression of immune markers in a p53-/mouse model. (a) Gene expression of CCL2 and CCL4.
(b) Gene expression of NRP1 and ARG1. (c) Gene
expression of TGFΒ1 and TGFΒ3. (d) Gene expression of
IL-4 and IL-10. (e) Gene expression of Aldh1a1 and
Aldh1a2. (f) Gene expression of IFNγ and IDO-1. (g)
Gene expression of IL6 and Cox2. (h) Gene expression of
iNOS and IL1β.
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Figure 10. Protein expression of immune and angiogenic markers in p53-/- mouse
model exposed to 3000 µg/kg/day BP3 during pregnancy and lactation. (a) CD-31(b)
FoxP3 (c) ARG1 (d) Gr-1 (e) CD25
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Chapter 4
DISCUSSION AND CONCLUSION
Discussion
In this study we sought to determine if BP3 induced changes in myeloid cell interactions
in the immune system through ER mediated mechanisms. We focused on answering two
main questions:
1. Does BP3 alter macrophage polarization, cytokine/chemokine secretion, viability in
vitro?
2. Does exposure to BP3 in vivo during pregnancy/lactation affect the RNA expression
of cytokines and immunosuppressant factors associated with myeloid population?
Previous data has shown that BP3 can increase the cytokine CCL18. This cytokine is
present in dendritic cells and is an M2 marker in human breast tissue. This led us to
investigate whether BP3 exposure pushes macrophages towards either an M1 or M2
phenotype when there is an absence of other inflammatory signals. Numerous EDCs
including BP3 have been demonstrated to affect chemokine expression. They are
important for dictating which populations of cells arrive at the tumor location. Our results
indicate an elevation of CCL2 by BP3 under certain circumstances, MO not TAM. This
suggests that BP3 might have a different effect when there is cancer present versus no
cancer. This also might suggest a reason for why the Schwartz lab observed a protective
effect of BP3 on one diet and not on the other.
We chose to study the 4T1 triple negative cell line as well as the Raw 264.7
macrophage cell line because of their extensive use in previous research. The 4T1 tumor
cell line was important in establishing whether BP3 could have an effect even when no
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receptors were present. Additionally, the Raw 264.7 cell line has been shown to polarize
towards M1 in previous literature and this is important throughout my thesis in order to
create a baseline when creating the M1 or TAM phenotype.
Our results show that when inflammatory signals are absent BP3 alone does not push
M0 cells towards the M1 or M2 phenotype. When analyzing gene expression of the M1
cytokines including IL6, TNFα, and IL1β there was no change. Following gene
expression analysis, protein analysis using the MSD confirmed that there was no change
in the secreted protein levels either. Additionally, there was no statistically significant
change in M2 biomarker expression. There was a general increasing trend in chemokine
RNA expression and chemokine receptor expression, but this did not reach significance.
In cells expressing the M1 phenotype, BP3 showed an increasing trend in TNFα,
IL1β, and Cox2 expression. This change was not observed in IL6 gene expression. As
expected from the lack of change in IL6 gene expression there was also no change in
secreted protein expression of IL6. Interestingly, the protein expression of IL1β was not
upregulated as was seen in the RNA expression.
When looking at secreted protein expression via MSD in the resolution macrophages,
it is evident that BP3 increases TNFα protein expression at 72 hours. This is especially
important when placed in the context of resolution. If proper resolution does not occur in
the body, this can lead to a chronic low level inflammation. Diseases that could follow
this unresolved inflammatory response includes diabetes, cardiovascular disease, cancer,
arthritis, and chronic obstructive pulmonary disease (Minihane et al. 2015). Our results
showed no change in total cells but an increase in viable cells, determined by MTS. This
assay targets an enzyme in the mitochondria and is a sign of metabolic activity. Future
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work should be done in order to determine if there is prolonged SDH, a marker of
metabolic activity, following BP3 exposure.
BP3 altered the polarization of RAW macrophages towards TAMs after coincubation with tumor cells from the 4T1 cell line. When examining the recovery phase
of M1, BP3 was found to reduce IL1β, IL6 and TNFα during LPS activation. It does not
appear to affect the resolution of the protein levels except for TNFα which appears to be
elevated for longer. This suggests that BP3 may affect the metabolic activity. In
particular this may relate to mitochondrial succinate dehydrogenase. 4T1s treated with
M0 conditioned media showed a significant increase in secondary colonies.
We expected BP3 to have a stronger effect on macrophage polarization. In RAW
264.7 cells, stimulated with LPS, E2 treatment suppressed its ability to polarize towards
the pro-inflammatory phenotype (Kim, 2003: Tomaszewska, 2003). While BPA has been
shown to stimulate pro-inflammatory pathways (Yamashita, 2015). Based on this we
expected a result similar to BPA and it is interesting that BP3 did not appear to have this
effect in our research.
We sought to determine whether BP3 treatment of RAW264 cells affected the
release of any protein which affects activation induced T cell proliferation or gene
expression. We found that there is a general decrease in cell proliferation following
exposure to conditioned media from BP3 treated RAW but no change in viability. There
is also a significant decrease in cytokine secretion. It is unclear whether this was due to a
direct effect or an indirect effect.
The p53 model causes several subtypes of breast cancer. Klara Matouskova was able
to identify different tumor types in her study and this could show how the impact of BP3
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on the tumor directly or the immune population may be dictated by these subtypes. A
limitation of the protein analysis is that within the vehicle and BP3 exposed mice, there
are several different tumor types and tumor grades. This could be associated with the
variability seen in each treatment group between mice. Future work should be done in
order to increase the number of tumor samples in each subtype in order to draw proper
conclusions from the results.
In the p53-/- tumor experiment animals were exposed to 3mg/kg/day during
pregnancy and lactation. This dosage was also used by the Joe Jerry lab, where they
found BP3 causes permanent damage to ductal density in mice (Jerry et al. 2018). By
using the p53-/- mouse tumors we found that exposure to 3mg/kg/day BP3 during
pregnancy and lactation did not result in a residual effect on most markers of macrophage
or dendritic cell activity in tumors a year later. However, interestingly there was a change
in IDO1 expression showing an increased expression of IDO1. IDO1 RNA expression
was not associated with markers of immunosuppressive cell types, but did appear to
correlate with increased large vessels in tumors and a decrease in micro vessels (CD31).
As an angiogenesis marker that is associated with immunosuppressed environments such
as Tregs or MDSC populations, CD31 was expected to increase based on an increase in
blood vessels analyzed through H&E in these tumors. Our results show a decrease in
CD31 expression suggesting that the CD31 marker may be more sensitive to staining all
blood vessels which may not be quantifiable via IHC.
GR-1 is expressed in neutrophils and myeloid derived suppressor cells and we found
a slight decrease in protein expression in the oxybenzone exposed group. Additionally, by
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using the FoxP3 marker we saw no change in Tregs between both groups. The CD25
marker which also marks Tregs and tolerogenic dendritic cells had no change as well.
Conclusion
Oxybenzone is a ubiquitous chemical that is going to continue to be used to
protect humans from UV exposure as well as in consumer products. Therefore, it is
important to consider its effects as it is constantly absorbed by the body. Although
oxybenzone is not as thoroughly researched as other endocrine disrupting chemicals, such
as BPA, does not mean that it is not causing harmful effects to the body, particularly in
the immune system.
We observed an interesting impact on anchorage independent growth of 4T1. It is
important to consider that anchorage independent growth is cell growth without adhesion
and this is a marker for stem like abilities. Our results show that there is a protein that
could be elevated in M0 following BP3 exposure. Further exploration is necessary in
order to determine the mechanism involved in the changes we observed.
We also observed significant decreases in the activation induced T cell cytokines
secretion in the presence of conditioned media from BP3 treated M0. In the future it is
necessary to extend this research in order to determine whether the changes seen were
due to a BP3 dependent effect or due to the secreted proteins from macrophages.
Potential future direction to continue this project includes, using the p53-/- mouse
model to stain more tissue samples and analyze RNA from other tumors that were not
included in this thesis. The original experiment had a larger group of mice in the vehicle
and BP3 treatment groups and adding more samples would increase the validity of the
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results and may help to identify if there is a correlation in tumor type and protein
expression of the immune and angiogenic marker.
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Appendix
Methods
Chemicals
DMSO was used as the control.
30uM BP3 was used as the standard exposure.
Conditioned Media
Once cells were cultured for 48 hours or 72 hours, the supernatant from the 6-well plates
was centrifuged at 1000g, collected, and aliquoted into microcentrifuge tubes and stored
in the 4 degree fridge.
Cell Culture
-

4T1 Direct Treatment

Using 10cm plates, 4T1s were cultured in … media and once they reached 75%
confluency they were plated into 6-well plates where n=3 for DMSO and 30uM BP3
exposure. DMSO and BP3 was added directly to the media at 1:1000.
-

4T1 Indirect Treatment

Using 10cm plates, 4T1s were cultured in … media and once they reached 75%
confluency they were plated into 6-well plates where n=3 for DMSO conditioned media
and n=3 for BP3 conditioned media
-

Raw 264.7 (M0)

Using 10cm plates, Raw 264.7 were cultured in RPMI media and once they reached 75%
confluency they were plated into 6-well plates where n=3 for DMSO and 30uM BP3
exposure. DMSO and BP3 was added directly to the media at 1:1000.
-

M1
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Using 10cm plates, Raw 264.7 were cultured in RPMI media and once they reached 75%
confluency they were plated into 6-well plates where n=3 for DMSO and 30uM BP3
exposure. DMSO and BP3 was added directly to the media at 1:1000. Additionally
Lipopolysaccharide (LPS) was added to each well at a concentration of 10nM.
-

Co-culture of 4T1s and Raw 264.7 (TAMs)

Cells were treated in triplicate with DMSO control or 30uM BP3 for 48 hours using 6well plates.
-

M1 recovery

Raw 264.7 cells were stimulated with LPS and treated with DMSO or 30uM BP3 for 48
hours and then replacing the media with fresh untreated RPMI media for varying time
periods.
-

Primary T cells

After being euthanized with CO2, spleens from Balb/C mice were dissociated and using
the … kit T cells were cultured and treated with DMSO or 30uM BP3.
Cell viability/proliferation (MTS Assay)
After cell culture in their respective treatment paradigm, 10uL of cell titer 96 Aqueous
one solution was added to each well. The cells incubated at 37 degrees Celsius for 4
hours and absorbance was measured at 490nm using a 96-well plate reader. The values
were then recorded and analyzed using the statistical analysis method described below.
Cell migration
We examined the direct exposure on migration using a scratch wound assay.
Using 10cm plates, 4T1s were cultured in … media and once they reached 75%
confluency they were plated into 6-well plates in triplicate and treated with DMSO or
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30uM BP3. Using a sterile pipette tip, a vertical scratch was made in the middle of each
well. The length of the scratch wound was measured at 0hr, 8hr, and 24hr to determine
the rate of migration and pictures were taken using Nikon Eclipse TE2000-Uusing
Metaview™ software.
Anchorage Independent Growth
We plated 4T1 cells at a low density on low attachment cell culture plates and looked for
growth of primary and secondary colonies. 4T1s were plated as single cells and cultured
for 1 week. After 1 week the cells, now in colonies, were resuspended and re-plated in
the same treatment groups for another week. After week 2 colonies were measured and
any colony above 40um was quantified in each treatment group. Images of
mammosphere formation were captured with a Nikon Eclipse TE2000-Uusing
Metaview™ software.
Gene expression and analysis
Total RNA from all cell lines was extracted in triplicate for each treatment using an acid–
phenol extraction procedure, according to the manufacturer’s instructions (TRIzol,
Invitrogen, Carlsbad, CA, USA). Relative expression levels of mRNA were determined
by quantitative real‐time PCR using the Mx3005P real‐time PCR system (Agilent, Santa
Clara, CA, USA) and all values were normalized to the amplification of an appropriate
normalizer gene. The assays were performed using the 1‐Step Brilliant SYBR Green III
QRT‐PCR Master Mix Kit (Agilent) containing 200 nM forward primer, 200 nM reverse
primer and 10 ng total RNA. The conditions for complementary DNA synthesis and
target mRNA amplification were as follows: 1 cycle of 50°C for 30 min; 1 cycle of 95°C
for 10 min and 35 cycles each of 95°C for 30 s, 55°C for 1 min and 72°C for 30 s.
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Nontemplate controls were included to control for primer dimers and no reverse
transcriptase controls were included to control for genomic DNA amplification.
Quantitative analysis was carried out as follows: Ct values were assigned for each sample
using an automatic threshold level determined by the Mx3000P software. Delta Ct (dCt)
values were determined according to the following formula: dCt(target gene) = Ct(target
gene) – Ct(housekeeping gene). Changes in gene expression are shown as RQ values and
calculated using the following formula: RQ = 2−ddCt, where ddCt values were calculated as
ddCt = dCt(sample) – dCt(reference sample) (Gregory et al. 2020).
Protein Expression
-

Immunohistochemistry

Immunohistochemistry (IHC) was performed on a DakoCytomation autostainer using the
Envision HRP Detection system (Dako, Carpinteria, CA). Each mammary tissue block
was sectioned at 4 μm on a graded slide, deparaffinized in xylene, rehydrated in graded
ethanols, and rinsed in Tris-phosphate-buffered saline (TBS). Heat induced antigen
retrieval was performed in a microwave at 98°C in 0.01 M citrate buffer. After cooling
for 20 minutes, sections were rinsed in TBS and subjected to the primary rabbit
polyclonal antibody for 45 minutes. Immunoreactivity was visualized by incubation with
chromogen diaminobenzidine (DAB) for 5 minutes. Tissue sections were counterstained
with hematoxylin, dehydrated through graded ethanols and xylene, and cover-slipped.
Images were captured with an Olympus BX41 light microscope using SPOTSOFTWARE
(Gauger, 2012).
-

ELISA
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Following cell culture and collection of conditioned media (detailed above), V-Plex pro
inflammatory panel 1 mouse from Meso scale discovery and it was run according to
manufacturer’s instructions. The analysis was run on discovery workbench.
Statistical Analysis
Group means were compared using Student’s t‐tests and overall patient responses were
analyzed using a Wilcoxon signed‐rank test using GraphPad Prism version 6 (GraphPad
Software, La Jolla, CA, USA). A P value of <0.05 was considered significant (Gregory et
al. 2020).
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